In transition-age childhood-onset growth hormone deficiency, growth hormone response to the glucagon stimulation test depends mainly on pituitary dysfunction severity, with BMI having minimal impact.

A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...

Glucagon, secreted by pancreatic α-cells, plays a crucial role in glucose metabolism through its counter-regulatory effects ...

City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by ...

Losing weight is best done with medical supervision.

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

New fleet of weight loss drugs are more effective than the current popular obesity medications at trial - One in eight ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the improvement of other conditions in longer studies.

Accepting the toxicity data submitted by Macleods Pharmaceuticals, the Subject Expert Committee (SEC) functioning under the ...